HLA-C*16 Product Insert Page 1 of 20

101.627-12 – including *Taq* **polymerase**General "Instructions for Use"

IFU-01 Rev. No. 01 can be downloaded from

Lot No.: 21K Lot-specific information www.olerup-ssp.com

Olerup SSP® HLA-C*16

Product number: 101.627-12 – including *Taq* polymerase

Lot number: 21K

Expiry date: 2012-June-01

Number of tests: 12 Number of wells per test: 15

Storage - pre-aliquoted primers: dark at -20°C

PCR Master Mix: -20°C
 Adhesive PCR seals
 Product Insert
 RT

This Product Description is only valid for Lot No. 21K.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® HLA-C*16 LOT

The HLA-C*16 specificity and interpretation tables have been updated for the HLA-C alleles described since the previous *Olerup* SSP® HLA-C*16 lot was made (Lot No. 69F).

Seven wells has been added to the C*16 kit, wells **9** to **15**.

The amplification patterns for some rare HLA-C*16 alleles only differ by the length of the specific PCR products.

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale			
3	Moved	Moved	Primer pair moved to well 9.			
4	-	- Exchanged positive control primer pa				
9	Added	Added	Primer pair from well 3.			
10	New	New	New primer pairs for the C*16:13 and C*16:19 alleles.			
11	New	New	New primer pairs for the C*16:15 and C*16:20 alleles.			

(E

HLA-C*16 Product Insert Page 2 of 20 101.627-12 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 01 can be downloaded from

12	New	New	New primer pairs for the C*16:16Q and
			C*16:17 alleles.
13	New	New	New primer pair for the C*16:14 alleles.
14	New	New	New primer pair for the C*16:18 allele.
15	New	New	New primer pair for the C*16:21 allele.

HLA-C*16 Product Insert Page 3 of 20 101.627-12 – including *Tag* polymerase General "Instructions for Use"

101.627-12 – including *Taq* **polymerase**General "Instructions for Use"

IFU-01 Rev. No. 01 can be downloaded from

Lot No.: 21K Lot-specific information www.olerup-ssp.com

PRODUCT DESCRIPTION

HLA-C*16 SSP typing

CONTENT

The primer set contains 5'- and 3'-primers for identifying the C*16:01 to C*16:21 alleles.

PLATE LAYOUT

Each HLA-C*16 test consists of 15 PCR reactions in a 16 well cut PCR plate. Well 16 is empty.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	empty

The 16 well PCR plate is marked with 'HLA-C*16' in silver/gray ink.

Well No. 1 is marked with the Lot No. '21K'.

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 16 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

The interpretation of HLA-C*16 SSP subtypings will be influenced by many other HLA-C alleles, when present on the other haplotype. In addition, primer mix 4 will amplify the B*35:08:02 and B*67:02 alleles, and primer mix 11 will amplify the A*24:73, B*07:66 and B*51:55 alleles.

UNIQUELY IDENTIFIED ALLELES

All the HLA-C*16 alleles, i.e. **C*16:01 to C*16:21**, recognized by the HLA Nomenclature Committee in April 2010¹ will be amplified by the primers in the HLA-C*16 SSP kit.

The HLA-C*16 primer set cannot distinguish the C*16:01:01, C*16:01:03 and C*16:01:04 alleles or the C*16:02:01 to C*16:02:04 alleles.

The C*16:15 and C*16:20 alleles may be distinguished by the different sizes of the specific PCR products generated by primer mix 11.

The C*16:16Q and C*16:17 alleles may be distinguished by the different sizes of the specific PCR products generated by primer mix 12.

¹HLA-C alleles listed on the IMGT/HLA web page 2010-April-01, 3.0.0, www.ebi.ac.uk/imgt/hla.

November 2010 Rev. No.: 00

Lot No.: 21K Lot-specific information www.olerup-ssp.com

RESOLUTION IN HOMO- AND HETEROZYGOTES

The 19 phenotypically different HLA-C*16 alleles give rise to 18 amplification patterns, as some alleles have patterns that only differ in size of specific PCR product. These can be combined in 171 homozygous and heterozygous combinations. 93 of these genotypes do not give rise to unique amplification patterns. The different lengths of the specific PCR products generated by primer mixes 6, 7, 10, 11 and 12 were not considered in these calculations.

```
++-+++- ------ 16:06,16:09 = 16:09,16:10 = 16:09,16:11
++-++-- +-----16:06,16:12 = 16:10,16:12 = 16:11,16:12
++-++-- -+----16:06,16:19 = 16:10,16:19 = 16:11,16:19
++-++-- ----- 16:02,16:06 = 16:02,16:10 = 16:02,16:11
++-++-+ -+----16:07,16:19 = 16:09,16:13
++-++-+- ----- 16:01,16:09 = 16:02,16:07 = 16:07,16:09
++-++--- -+----16:01,16:19 = 16:02,16:13 = 16:13,16:19
++--+-+ -----16:01:02,16:09 = 16:02,16:09 = 16:09,16:09
++--+-- +----16:01:02,16:12 = 16:02,16:12 = 16:12,16:12
++--+-- -+----16:01:02,16:19 = 16:02,16:19 = 16:19,16:19
++--+--- 16:01:02,16:02 = 16:02,16:02
+-++++-- ------ 16:04:01,16:06 = 16:04:01,16:11
+-+++--- -16:01,16:04:01 = 16:01:02,16:04:01
+--+++- -----16:07,16:10 = 16:07,16:11
+--+++-+ ------16:06,16:08 = 16:08,16:10 = 16:08,16:11
+--+++-- -+----16:06,16:13 = 16:10,16:13 = 16:11,16:13
+--+++-- --+---16:06,16:15 = 16:10,16:15 = 16:11,16:15
+--+++-- ---+-- 16:06,16:16Q = 16:10,16:16Q = 16:11,16:16Q
+--++-- ----+-- 16:06,16:14 = 16:10,16:14 = 16:11,16:14
+--+++-- ----+-16:06,16:18 = 16:10,16:18 = 16:11,16:18
+--++-- ----+16:06,16:21 = 16:10,16:21 = 16:11,16:21
+--++-- ----- 16:01,16:06 = 16:01,16:10 = 16:01,16:11 =
                16:01:02,16:06 = 16:01:02,16:10 = 16:01:02,16:11 =
                16:06,16:10 = 16:06,16:11 = 16:10,16:11 =
                16:11,16:11
+--++-+ -----16:01,16:07 = 16:01:02,16:07
+--++--+ -----16:01,16:08 = 16:01:02,16:08 = 16:08,16:08
+--++--- -+----16:01,16:13 = 16:01:02,16:13 = 16:13,16:13
+--++--- --+--- 16:01,16:15 = 16:01:02,16:15 = 16:15,16:15
+--++--- ---+--- 16:01,16:16Q = 16:01:02,16:16Q = 16:16Q,16:16Q
+--++--- ---+--16:01,16:14 = 16:01:02,16:14 = 16:14,16:14
+--++--- ----+-16:01,16:18 = 16:01:02,16:18 = 16:18,16:18
+--++--- ----+16:01,16:21 = 16:01:02,16:21 = 16:21,16:21
+--++--- 16:01,16:01 = 16:01,16:01:02
16:01 = 16:01:01, 16:01:03 \text{ and } 16:01:04
16:02 = 16:02:01-16:02:04
16:15 = 16:15 \text{ and } 16:20
16:16Q = 16:16Q and 16:17
```

General "Instructions for Use" IFU-01 Rev. No. 01 can be downloaded from

Lot No.: 21K Lot-specific information www.olerup-ssp.com

SPECIFICITY TABLE

HLA-C*16 SSP subtyping

Specificities and sizes of the PCR products of the 15 primer mixes used for HLA-C*16 SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA- C*16 alleles ³	Other amplified HLA Class I alleles ⁴
1	205 bp	800 bp	*16:01:01- 16:02:04, 16:04:01, 16:08- 16:21	*06:31
2	340 bp	1070 bp	*16:02:01- 16:02:04, 16:09, 16:12, 16:19	*01:14, 02:02:01-02:02:03, 02:02:05-02:11, 02:13-02:26:02, 02:28-02:36, 03:07, 03:15, 03:45, 04:01:01:01-04:01:16, 04:03-04:10, 04:12-04:20, 04:23-04:28, 04:30-04:35, 04:37-04:54, 04:56-04:62, 05:01:01:01-05:01:13, 05:03-05:42, 06:02:01:01-06:02:01:02, 06:02:03-06:10, 06:12-06:37, 07:07, 07:09, 07:49, 07:76, 08:10, 12:04:01-12:05, 12:09, 12:21, 12:33, 14:04, 14:12, 15:02:01-15:06:02, 15:08-15:13, 15:15-15:20, 15:22-15:24, 15:26-15:28, 17:01:01:01-17:06, 18:01-18:03
3 ⁶	220 bp	800 bp	*16:04:01	*01:04, 01:09, 02:05, 02:17, 06:02:01:01-06:02:01:02, 06:02:03-06:03, 06:07-06:13, 06:15-06:34, 06:36-06:37, 12:03:01:01-12:07, 12:11-12:13, 12:15, 12:23, 12:25-12:26, 12:28-12:29, 12:31-12:35, 14:16
4 ⁵	140 bp	800 bp	*16:01:01, 16:01:03- 16:01:04, 16:04:01, 16:06- 16:08, 16:10- 16:11, 16:13- 16:18, 16:20- 16:21	*01:21, 02:12 ^w , 02:27, 04:11, 04:29, 04:36, 04:55, 07:02:09, 08:01:01-08:09, 08:11-08:31, 12:02:01-12:03:03, 12:03:05-12:03:08, 12:03:10-12:03:11, 12:06-12:08, 12:10:01-12:20, 12:22-12:26, 12:28-12:32, 12:34-12:35, 14:02:03, 14:03, 14:08, 14:10, 15:07, 15:21 ^w , 15:25, B*35:08:02, B*67:02

Lot No.: 21K	Lot-specific information	www.olerup-ssp.com
--------------	--------------------------	--------------------

5	160 bp	800 bp	*16:01:01- 16:02:04, 16:06- 16:09, 16:11- 16:21	*07:53
6 ^{5,8}	130 bp,160 bp, 210 bp	1070 bp	*16:06, 16:10- 16:11	*02:21
7 ^{5,9}	100 bp, 210 bp	1070 bp	*16:07, 16:09	*02:34
8 ⁵	135 bp	1070 bp	*16:08	
_				
9 ⁵	85 bp	1070 bp	*16:12	
10 ¹⁰	215 bp, 350 bp	800 bp	*16:13, 16:19	*07:24
11 ¹¹	170 bp, 540 bp	1070 bp	*16:15, 16:20	*04:14, 07:53, A*24:73, B*07:66, B*51:55
12 ^{5,7,12}	105 bp, 245 bp	1070 bp	*16:16Q-16:17	*01:27
13 ⁵	130 bp	1070 bp	*16:14	*06:32
14 ⁷	210 bp	1070 bp	*16:18	
15 ⁵	145 bp	1070 bp	*16:21	*02:14, 04:42, 06:05, 07:02:09, 12:16, 15:23

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-C*16 high resolution SSP typings.

When the primers in a primer mix can give rise to specific PCR products of more than one length this is indicated if the size difference is 20 base pairs or more. Size differences shorter than 20 base pairs are not given. For high resolution SSP kits the respective lengths of the specific PCR product(s) of the alleles amplified by these primer mixes are given.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-C*16 SSP subtyping.

In addition, wells number 3 to 5 and 10 contain the primer pair giving rise to the shorter, 800 bp, internal positive control band.

In the presence of a specific amplification the intensity of the control band often decreases.

³The C*16:15 and C*16:20 alleles may be distinguished by the different sizes of the specific PCR products generated by primer mix 11.

The C*16:16Q and C*16:17 alleles may be distinguished by the different sizes of the specific PCR products generated by primer mix 12.

HLA-C*16 Product Insert Page 7 of 20 101.627-12 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 01 can be downloaded from

Lot No.: 21K Lot-specific information www.olerup-ssp.com

⁴Due to the sharing of sequence motifs between HLA-C alleles non-HLA-C*16 alleles will be amplified by primer mixes 1 to 7, 10 to 13 and 15. In addition, primer mix 4 will amplify the B*35:08:02 and B*67:02 alleles, and primer mix 11 will amplify the A*24:73, B*07:66 and B*51:55 alleles.

⁵Short specific PCR fragments are less intense and not as sharp as longer specific bands.

⁶Primer mix 3 may give a lower yield of specific PCR product than the other C*16 primer mixes.

⁷Primer mixes 12 and 14 may have tendencies of unspecific amplifications.

⁸Primer mix 6: Specific PCR fragment of 130 bp in the C*16:11 and in the C*02:21 allele. Specific PCR fragment of 160 bp in the C*16:10 allele. Specific PCR fragment of 210 bp in the C*16:06 allele.

⁹Primer mix 7: Specific PCR fragment of 100 bp in the C*16:09 and in the C*02:34 alleles. Specific PCR fragment of 210 bp in the C*16:07 allele.

¹⁰Primer mix 10: Specific PCR fragment of 215 bp in the C*16:19 allele. Specific PCR fragment of 350 bp in the C*16:13 and in the C*07:24 alleles.

¹¹Primer mix 11: Specific PCR fragment of 170 bp in the C*16:20 and in the A*24:73, B*07:66 and

¹¹Primer mix 11: Specific PCR fragment of 170 bp in the C*16:20 and in the A*24:73, B*07:66 and B*51:55 alleles. Specific PCR fragment of 540 bp in the C*16:15 and in the C*04:14 and 07:53 alleles.

¹²Primer mix 12: Specific PCR fragment of 105 bp in the C*16:17 and in the C*01:27 alleles. Specific PCR fragment of 245 bp in the C*16:16Q allele. 'w' might be weakly amplified.

November 2010

Rev. No.: 00

General "Instructions for Use" IFU-01 Rev. No. 01 can be downloaded from

Lot No.: 21 K Lot-specific information www.olerup-ssp.com

INTERPRETATION TABLE **HLA-C*16 SSP subtyping** Amplification patterns of the HLA-C*16:01 to 16:21 alleles Well⁷ Length of spec. PCR product(s) Length of int. pos. control¹ 5'-primer(s)² 1St I 5' -AgT 3' 5' -CgA 3' 5' -AgT 3' 5' -CCA 3' 5' -gTC 3' 5' -CCA 3' 5' -CGC 3' 5' -ggA 3' 5' -gTC 3' 5' -TAC 3' 5' -Agg 3' 3'-primer(s)³ 5' -CCg 3' 5' -ggT 3' 5' -CCA 3' 5' -ggC 3' 5' -TCT 3' 5' -CTT 3' 5' -ggT 3' 5' -CgA 3' 5' -CCg 3' 5' -TCT 3' 5' -TCT 3' Well No. HLA-C allele⁴ *16:01:01, 16:01:03-16:01:04 *16:01:02 *16:02:01-16:02:04 *16:04:01 *16:06 *16:07 *16:08 *16:09 *16:10 *16:11 *16:12 *16:13 *16:14 *16:15, 16:20⁵ *16:16Q, 16:17⁶ *16:18 *16:19 *16:21

Well No.

General "Instructions for Use" IFU-01 Rev. No. 01 can be downloaded from

			INT	ERPF	RETA	ΓΙΟΝ ⁻	TABLE
			HL	_ A-C *1	6 SSF	subt	vpina
	Α	mplifica					6:01 to 16:21 alleles
			Well ⁷				
9	10	11	12	13	14	15	
85	215	170	105	130	210	145	Length of spec.
	350	540	245	100	210	140	PCR product(s)
	000	040	240				1 On product(s)
1070	800	1070	1070	1070	1070	1070	Length of int.
							pos. control ¹
256	385	289	361	126	368	97	5'-primer(s) ²
^{5'} -ACg ^{3'}		^{5'} -Agg ^{3'}	^{5'} -AgT ^{3'}		^{5'} -gTg ^{3'}	^{5'} -TCg ^{3'}	5 p
_	523	409	_		_	_	
		^{5'} -ggC ^{3'}					
302	3 rd I	539	427	214	539	201	3'-primer(s) ³
^{5'} -ggT ^{3'}	^{5'} -CTC ^{3'}	5' -TCT 3'	^{5'} -gTA ^{3'}	5' -CCA 3'	5' -TCT 3'	5' -CTT 3'	
			563				
			^{5'} -CgT ^{3'}				
9	10	11	12	13	14	15	Well No.
							HLA-C allele ⁴
							*16:01:01, 16:01:03-16:01:04
							*16:01:02
							*16:02:01-16:02:04
							*16:04:01
							*16:06
							*16:07
							*16:08
							*16:09
							*16:10
							*16:11
9	40						*16:12
	10			42			*16:13
		44		13			*16:14
		11	40				*16:15, 16:20 ⁵
			12		4.4		*16:16Q, 16:17 ⁶
					14		*16:18
	40						140 401
	10					A E	*16:19
9	10	11	12	13	14	15 15	*16:19 *16:21 Well No.

Length of spec.	205	340	220	140	160	130	100	135
PCR product(s)						160	210	
						210		
Well No.	1	2	3	4	5	6	7	8
*01:04, 01:09, 06:11, 12:03:04,			3					
12:03:09, 14:16			J					
*01:14, 02:02:01-02:02:03,								
02:02:05-02:04, 02:06-02:11,								
02:13, 02:15-02:16:02, 02:18-								
02:20, 02:22-02:26:02, 02:28-								
02:33, 02:35-02:36, 03:07,								
03:15, 03:45, 04:01:01:01-								
04:01:16, 04:03-04:10, 04:12-								
04:13, 04:15:01-04:20, 04:23-								
04:28, 04:30-04:35, 04:37-								
04:41, 04:43-04:54, 04:56-		2						
04:62, 05:01:01:01-05:01:13,		_						
05:03-05:42, 06:04, 06:06,								
06:14, 06:35, 07:07, 07:09,								
07:49, 07:76, 08:10, 12:09,								
12:21, 14:04, 14:12, 15:02:01-								
15:06:02, 15:08-15:13, 15:15-								
15:20, 15:22, 15:24, 15:26-								
15:28, 17:01:01:01-17:06,								
18:01-18:03								
*01:21, 02:27, 04:11, 04:29,								
04:36, 04:55, 08:01:01-08:09,								
08:11-08:31, 12:02:01-								
12:02:05, 12:08, 12:10:01-				4				
12:10:02, 12:14:01-12:14:02,				4				
12:17-12:20, 12:22, 12:24,								
12:30, 14:02:03, 14:03, 14:08,								
14:10, 15:07, 15:25,								
B*35:08:02, B*67:02								
*01:27								
*02:05, 02:17, 06:02:01:01-								
06:02:01:02, 06:02:03-06:03,								
06:07-06:10, 06:12-06:13, 06:15-		2	3					
06:30, 06:33-06:34, 06:36-								
06:37, 12:04:01-12:05, 12:33								
*02:12, 15:21				W				
*02:14, 04:42, 06:05, 15:23		2						
Well No.	1	2	3	4	5	6	7	8

85	215	170	105	130	210	145	Length of spec.
03	350	540	245	130	4 10	140	PCR product(s)
	330	340	245				FCK product(s)
9	10	11	12	13	14	15	Well No.
<u> </u>	10		12	13	17	13	*01:04, 01:09, 06:11, 12:03:04,
							12:03:09, 14:16
							*01:14, 02:02:01-02:02:03,
							02:02:05-02:04, 02:06-02:11,
							02:13, 02:15-02:16:02, 02:18-
							02:20, 02:22-02:26:02, 02:28-
							02:33, 02:35-02:36, 03:07,
							03:15, 03:45, 04:01:01:01-
							04:01:16, 04:03-04:10, 04:12-
							04:13, 04:15:01-04:20, 04:23-
							04:28, 04:30-04:35, 04:37-
							04:41, 04:43-04:54, 04:56-
							04:62, 05:01:01:01-05:01:13,
							05:03-05:42, 06:04, 06:06,
							06:14, 06:35, 07:07, 07:09,
							07:49, 07:76, 08:10, 12:09,
							12:21, 14:04, 14:12, 15:02:01-
							15:06:02, 15:08-15:13, 15:15-
							15:20, 15:22, 15:24, 15:26-
							1 1
							15:28, 17:01:01:01-17:06, 18:01-18:03
							*01:21, 02:27, 04:11, 04:29,
							04:36, 04:55, 08:01:01-08:09,
							08:11-08:31, 12:02:01-
							12:02:05, 12:08, 12:10:01-
							12:10:02, 12:14:01-12:14:02,
							1
							12:17-12:20, 12:22, 12:24,
							12:30, 14:02:03, 14:03, 14:08,
							14:10, 15:07, 15:25,
			12				B*35:08:02, B*67:02
			12				*01:27 *02:05, 02:17, 06:02:01:01-
							06:02:01:02, 06:02:03-06:03,
							06:07-06:10, 06:12-06:13, 06:15-
							· · · · · · · · · · · · · · · · · · ·
							06:30, 06:33-06:34, 06:36-
							06:37, 12:04:01-12:05, 12:33
						A E	*02:12, 15:21
	40	44	40	40	4.4	15	*02:14, 04:42, 06:05, 15:23
9	10	11	12	13	14	15	Well No.

Lot No.: 21K Lot-specific information www.olerup-ssp.com

Length of spec.	205	340	220	140	160	130	100	135
PCR product(s)						160	210	
						210		
Well No.	1	2	3	4	5	6	7	8
*02:21		2				6		
*02:34		2					7	
*04:14		2						
*06:31	1	2	3					
*06:32		2	3					
*07:02:09, 12:16				4				
*07:24								
*07:53					5			
*12:03:01:01-12:03:03,								
12:03:05-12:03:08, 12:03:10-								
12:03:11, 12:06-12:07, 12:11-			3	4				
12:13, 12:15, 12:23, 12:25-			3	4				
12:26, 12:28-12:29, 12:31-								
12:32, 12:34-12:35								
A*24:73, B*07:66, B*51:55								
Well No.	1	2	3	4	5	6	7	8

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-C*16 SSP subtyping.

In addition, wells number 3, 5 and 10 contain the primer pair giving rise to the shorter, 800 bp, internal positive control band.

²The nucleotide position, in the 2nd or 3rd exon or the 1st intron, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

The HLA-C*16:03 nucleotide sequence has been shown to be identical to C*14:03.

The HLA-C*16:04:02 nucleotide sequence has been shown to be identical to C*16:04:01.

The HLA-C*16:05 nucleotide sequence has been shown to be identical to C*16:04:01.
⁵The C*16:15 and C*16:20 alleles may be distinguished by the different sizes of the specific PCR

products generated by primer mix 11. The C*16:16Q and C*16:17 alleles may be distinguished by the different sizes of the specific PCR products generated by primer mix 12.

November 2010

Rev. No.: 00

Lot-specific information

IFU-01 Rev. No. 01 can be downloaded from

www.olerup-ssp.com

85 215 170 105 Length of spec. 130 210 145 350 PCR product(s) 540 245 9 11 13 Well No. 10 12 14 15 *02:21 *02:34 11 *04:14 *06:31 13 *06:32 15 *07:02:09, 12:16 10 *07:24 *07:53 11 *12:03:01:01-12:03:03. 12:03:05-12:03:08, 12:03:10-12:03:11, 12:06-12:07, 12:11-12:13, 12:15, 12:23, 12:25-12:26, 12:28-12:29, 12:31-12:32, 12:34-12:35 A*24:73, B*07:66, B*51:55 11 11 10 12 13 9 14 15 Well No.

Primer mix 7: Specific PCR fragment of 100 bp in the C*16:09 and in the C*02:34 alleles. Specific PCR fragment of 210 bp in the C*16:07 allele.

Primer mix 10: Specific PCR fragment of 215 bp in the C*16:19 allele. Specific PCR fragment of 350 bp in the C*16:13 and in the C*07:24 alleles.

Primer mix 11: Specific PCR fragment of 170 bp in the C*16:20 and in the A*24:73, B*07:66 and B*51:55 alleles. Specific PCR fragment of 540 bp in the C*16:15 and in the C*04:14 and 07:53 alleles.

Primer mix 12: Specific PCR fragment of 105 bp in the C*16:17 and in the C*01:27 alleles. Specific PCR fragment of 245 bp in the C*16:16Q allele.

'w' might be weakly amplified.

Lot No.: 21K

⁷Primer mix 6: Specific PCR fragment of 130 bp in the C*16:11 and in the C*02:21 allele. Specific PCR fragment of 160 bp in the C*16:10 allele. Specific PCR fragment of 210 bp in the C*16:06 allele.

		CE	LL LI	NE VA	۱L	ID	ΑT	'IC	N	S	HE	Ε	T						
	HLA-C*16 SSP primer set																		
											١	Nel	1						
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
					_	2	3	4	5	90	7	8	6(0	_	2	3	4	5
				ė	201073701	201073702	201073703	201073704	201073705	201073706	201073707	201073708	201073709	201073710	201073711	201073712	201073713	201073714	201073715
				Prod. No.	07	07	07	07	07	07	07	07	07	07	07	07	07	07	07
				Pro	201	201	201	201	201	201	201	201	201	201	201	201	201	201	201
	IHV	VC cell line		C*						- ,									
1	9001	SA	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280	LK707	*07:01	*15:05	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011	E4181324	*12:02		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
4	9275	GU373	*03:04	*04:01	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
5		KAS011	*06:02		-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
6	9353	SM	*03:04	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020		*05:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9007		*04:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026		*12:03		<u> </u>	-	+	+	-	-	-	-	-	-	-	-	-	-	-
10	9107		*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11		PITOUT	*16:01		+	-	-	+	+	-	-	-	-	-	-	-	-	-	-
12	9052		*06:02		-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
13		JESTHOM	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14		OLGA	*01:02	*03:04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075		*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	_
16		SWEIG007	*02:02		-	+	-	-	-	-	-	-	-	-	-	-	-	-	_
17		CTM3953540	*03:03	*07:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18		32367	*01:02	*07:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19		BM16	*07:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20		SLE005	*03:04		-	-	-	_	-	-	-	-	-	-	_	-	-	_	-
21		AMALA	*03:03		-	-	-	÷	-	-	-	-	-	-	-	-	-	-	-
22	9124	KOSE	*12:03	*15:02	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
24		JBUSH	*01:02 *12:03	15.02	-	+	-	-	-	-	÷	-	-	-	-	÷		÷	
25	9035		*08:02		Н		+	+							÷	÷		÷	
26		WT49	*07:01		Н	-	H	+		-	E	H		-	E	E	Ε	E	
27		CH1007	*07:04	*15:05	Ε.	+	-	H		-	E	-	-	-	Ė	Ė		H	
28		BEL5GB	*05:01	*16:01	+	+	-	+	+	-	-	-	-	-	-	-			-
29	9050		*16:01	10.01	+	-	H	+	+	-	E	-	Ė	-	E	E	Ε	÷	
30	9030		*17:01		Ι.	+	-	Ξ	_	-	-	-	-	-	-	-	E	E	
31		DUCAF	*05:01		 	+	-	-	-	-	-	-	<u> </u>	-	-	-	-	-	
32	9297		*17:01	*17:03	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
33		MT14B	*03:04		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104		*12:03		-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
35		SSTO	*05:01		-	+	Ė	Ė	-	-	-	-	-	-	-	-	-	-	-
36	9024		*03:03	*04:01	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
37		HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099		*03:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315		*02:02	*07:01	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134	WHONP199	*01:02	*06:02	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
41	9055	H0301	*08:02		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
42	9066	TAB089	*01:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076	T7526	*01:02	*08:01	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
44	9057	TEM	*12:03		-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
45		SHJO	*06:02	*17:01	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
46		SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47		TUBO	*07:04	*15:02	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303	TER-ND	*04:01	*16:01	+	+	-	+	+	-	-	-	-	-	-	-	-	-	-

HLA-C*16 Product Insert Page 15 of 20

101.627-12 – including *Taq* **polymerase**

General "Instructions for Use" IFU-01 Rev. No. 01 can be downloaded from

Lot No.: 21K Lot-specific information www.olerup-ssp.com

CERTIFICATE OF ANALYSIS

Olerup SSP® HLA-C*16 SSP

Product number: 101.627-12 – including *Taq* polymerase

Lot number: 21K

Expiry date: 2012-June-01

Number of tests: 12 Number of wells per test: 15

Well specifications:

Well No.	Production No.	Well No.	Production No.
1	2010-737-01	9	2010-737-09
2	2010-737-02	10	2010-737-10
3	2010-737-03	11	2010-737-11
4	2010-737-04	12	2010-737-12
5	2010-737-05	13	2010-737-13
6	2010-737-06	14	2010-737-14
7	2010-737-07	15	2010-737-15
8	2010-737-08		

The specificity of each primer solution of the HLA-C*16 primer set has been tested against 48 well characterized cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 6 to 15 were available. The specificity of the primers in primer solutions 6 to 8, 11, 14 and 15 were tested by separately adding one additional 5'-primer, respectively one additional 3'-primer. In primer solutions 8, 12 and 13 it was only possible to test the 3'-primer, the 5'-primer was not possible to test. In primer solution 10 it was only possible to test the 5'-primer, the 3'-primer was not possible to test. In primer solution 6 and 7 two respective one of the 5'-primers were not possible to test.

Results: No false positive or false negative amplifications were obtained.

Date of approval: 2010-November-24

Approved by:

Quality Control, Supervisor

HLA-C*16 Product Insert Page 16 of 20 101.627-12 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 01 can be downloaded from

Lot No.: 21K Lot-specific information www.olerup-ssp.com

Declaration of Conformity

Product name: Olerup SSP® HLA-C*16

Product number: 101.627-12

Lot number: 21K

Intended use: HLA-C*16 high resolution histocompatibility testing

Manufacturer: Olerup SSP AB

Hasselstigen 1

SE-133 33 Saltsjöbaden, Sweden

Phone: +46-8-717 88 27 **Fax:** +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2008 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex III, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at *Olerup* SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

The Authorized Representative located within the Community is: *Olerup* SSP AB.

Saltsjöbaden, Sweden 2010-November-24

Olle Olerup Managing Director HLA-C*16 Product Insert Page 17 of 20 101.627-12 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 01 can be downloaded from

HLA-C*16 Product Insert Page 18 of 20 101.627-12 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 01 can be downloaded from

HLA-C*16 Product Insert Page 19 of 20 101.627-12 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 01 can be downloaded from

HLA-C*16 Product Insert Page 20 of 20 101.627-12 – including *Taq* polymerase General "Instructions for Use"

IFU-01 Rev. No. 01 can be downloaded from

Lot No.: 21K Lot-specific information www.olerup-ssp.com

Addresses:

Manufacturer:

Olerup SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

Tel: +46-8-717 88 27 **Fax:** +46-8-717 88 18

E-mail: info-ssp@olerup.com

Web page: http://www.olerup-ssp.com

Distributed by:

Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00 **Fax:** +43-1-710 15 00 10

E-mail: support-at@olerup.com **Web page:** http://www.olerup.com

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-OLERUP1 **Fax:** 610-344-7989

E-mail: info.us@olerup.com

Web page: http://www.olerup.com

For information on Olerup SSP distributors worldwide, contact Olerup GmbH.